SCHEMBL13367203

SCHEMBL13367203

CCOC(=O)N1CCc2c(sc(NC(=O)CCc3cccc(C)c3)c2N)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 3/20 0.56
ADORA3 P0DMS8 1/20 0.56
POLB P06746 1/20 0.53
LMNA P02545 4/20 0.51
TP53 P04637 3/20 0.51
MAPT P10636 8/20 0.49
ALDH1A1 P00352 6/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
NPSR1 Q6W5P4 5/20 0.49
RXFP1 Q9HBX9 1/20 0.49
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 2/20 0.49
ALOX12 P18054 1/20 0.49
CASP1 P29466 1/20 0.49
MAPK1 P28482 1/20 0.48
TSHR P16473 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13037503 0.91 PDE4D (0.56) PDE4DADORA3POLBLMNATP53
SCHEMBL13038525 0.91 PDE4D (0.64) PDE4DADORA3POLBLMNATP53
SCHEMBL13334882 0.91 MAPT (0.54) PDE4DADORA3POLBLMNATP53
SCHEMBL13335194 0.89 PDE4D (0.52) PDE4DADORA3POLBLMNATP53
SCHEMBL3419073 0.87 L3MBTL1 (0.61) PDE4DADORA3POLBLMNATP53
SCHEMBL13367199 0.86 PDE4D (0.54) PDE4DADORA3POLBLMNATP53
SCHEMBL13367204 0.86 PDE4D (0.53) PDE4DADORA3POLBLMNATP53
SCHEMBL13037510 0.86 PDE4D (0.55) PDE4DADORA3POLBLMNATP53
SCHEMBL13334961 0.85 MAPT (0.53) PDE4DADORA3POLBLMNATP53
SCHEMBL13037509 0.82 POLB (0.49) PDE4DADORA3POLBLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714135-B2 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer 4SC AG (DE) 2010-05-11 US disclosed
US-20090227577-A1 TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER PEKARI KLAUS 2009-09-10 US disclosed
US-20080096914-A1 Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer ALTANA PHARMA AG (DE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096914-A1 Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer MKI67, CCNT1, RB1 PDE4D 4518/4885ADORA3 4355/4885POLB 1116/4885
US-20090227577-A1 TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER CCNO, CCNY, CCNT1 PDE4D 4699/4885ADORA3 2751/4885POLB 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.